Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer - PubMed (original) (raw)

Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer

H J Nielsen et al. BMJ. 1998.

No abstract available

PubMed Disclaimer

Figures

Figure

Survival in patients with colorectal cancer according to preoperative plasma concentrations of plasminogen activator inhibitor-1 (PAI-1). See text for definition of groups

Comment in

• Proteases as prognostic markers in cancer.
  Verspaget HW. Verspaget HW. BMJ. 1998 Mar 14;316(7134):790-1. doi: 10.1136/bmj.316.7134.790. BMJ. 1998. PMID: 9549443 Free PMC article. No abstract available.
• Association between plasma plasminogen activator inhibitor-1 and survival in colorectal cancer. Measuring C reactive protein concentrations may be more useful.
  Sattar N, McMillan DC. Sattar N, et al. BMJ. 1998 Sep 12;317(7160):750-1. doi: 10.1136/bmj.317.7160.750. BMJ. 1998. PMID: 9732351 Free PMC article. No abstract available.

Similar articles

• High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.
  Holten-Andersen MN, Stephens RW, Nielsen HJ, Murphy G, Christensen IJ, Stetler-Stevenson W, Brünner N. Holten-Andersen MN, et al. Clin Cancer Res. 2000 Nov;6(11):4292-9. Clin Cancer Res. 2000. PMID: 11106246
• Association between plasma plasminogen activator inhibitor-1 and survival in colorectal cancer. Measuring C reactive protein concentrations may be more useful.
  Sattar N, McMillan DC. Sattar N, et al. BMJ. 1998 Sep 12;317(7160):750-1. doi: 10.1136/bmj.317.7160.750. BMJ. 1998. PMID: 9732351 Free PMC article. No abstract available.
• Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
  Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Geurts-Moespot A, van Tienoven DT, Beex LV, Sweep FC. Manders P, et al. Cancer. 2004 Aug 1;101(3):486-94. doi: 10.1002/cncr.20374. Cancer. 2004. PMID: 15274061
• [New prognostic and predictive factors in advanced colorectal cancer].
  Gil-Bazo I, Páramo JA, García-Foncillas J. Gil-Bazo I, et al. Med Clin (Barc). 2006 Apr 15;126(14):541-8. doi: 10.1157/13087141. Med Clin (Barc). 2006. PMID: 16756907 Review. Spanish.
• [The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer].
  Herszényi L, Farinati F, Plebani M, István G, Sápi Z, Carraro P, De Paoli M, Naccarato R, Tulassay Z. Herszényi L, et al. Orv Hetil. 1999 Aug 15;140(33):1833-6. Orv Hetil. 1999. PMID: 10489782 Review. Hungarian.

Cited by

• Coculture of cancer cells with platelets increases their survival and metastasis by activating the TGFβ/Smad/PAI-1 and PI3K/AKT pathways.
  Tong H, Li K, Zhou M, Wu R, Yang H, Peng Z, Zhao Q, Luo KQ. Tong H, et al. Int J Biol Sci. 2023 Aug 15;19(13):4259-4277. doi: 10.7150/ijbs.85986. eCollection 2023. Int J Biol Sci. 2023. PMID: 37705745 Free PMC article.
• Human α-defensin 6 (HD6) suppresses CRC proliferation and metastasis through abolished EGF/EGFR signaling pathway.
  Wei PL, Lin JC, Hung CS, Makondi PT, Batzorig U, Chang TC, Huang CY, Chang YJ. Wei PL, et al. Int J Med Sci. 2022 Jan 1;19(1):34-46. doi: 10.7150/ijms.64850. eCollection 2022. Int J Med Sci. 2022. PMID: 34975297 Free PMC article.
• Circulating tumour cells and hypercoagulability: a lethal relationship in metastatic breast cancer.
  Kirwan CC, Descamps T, Castle J. Kirwan CC, et al. Clin Transl Oncol. 2020 Jun;22(6):870-877. doi: 10.1007/s12094-019-02197-6. Epub 2019 Aug 31. Clin Transl Oncol. 2020. PMID: 31473984 Free PMC article.
• VHL status regulates transforming growth factor-β signaling pathways in renal cell carcinoma.
  Mallikarjuna P, Sitaram RT, Landström M, Ljungberg B. Mallikarjuna P, et al. Oncotarget. 2018 Mar 27;9(23):16297-16310. doi: 10.18632/oncotarget.24631. eCollection 2018 Mar 27. Oncotarget. 2018. PMID: 29662646 Free PMC article.
• Transforming growth factor-β promotes aggressiveness and invasion of clear cell renal cell carcinoma.
  Sitaram RT, Mallikarjuna P, Landström M, Ljungberg B. Sitaram RT, et al. Oncotarget. 2016 Jun 14;7(24):35917-35931. doi: 10.18632/oncotarget.9177. Oncotarget. 2016. PMID: 27166254 Free PMC article.

References

1. 1. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L.Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985;44:139-266. - PubMed
2. 1. Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol. 1990;68:1–19. - PubMed
3. 1. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, et al. High level of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 1993;53:2513–2521. - PubMed
4. 1. Casslen B, Bossmar T, Lecander I, Åstedt B. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. Eur J Cancer. 1994;30A:1302–1309. - PubMed
5. 1. Meijer P, Pollet DE, Wauters J, Kluft C. Specificity of antigen assays of plasminogen activator inhibitor in plasma: Innotest plasminogen activator inhibitor-1 immunoassay evaluated. Clin Chem. 1994;40:110–115. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • HighWire
  • Ovid Technologies, Inc.
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information